Stock Market
As of Aug 19, U.S. stock index futures performed as follows: Dow Jones contracts edged up 0.13%, S&P 500 futures were little changed with a 0.02% gain, while Nasdaq 100 futures slipped 0.23%, pointing to a mixed tone as investors balanced blockbuster biotech news against rising-rate concerns.
Notable Stock Movers: Moderna (MRNA up 83.7% at $115.66) rocketed after upbeat melanoma vaccine data. Nebius (NBIS down 7.32% at $230.25) extended losses on fresh debt-financing plans.
SK Hynix’s U.S. shares (SKHY up 4% at $161.86) rebounded on a massive buyback announcement, while Apple and NVIDIA (NVDA up 0.39% at $220.60) traded narrowly mixed.
Among smaller caps, Yunji (YJ up 149.43% at $4.34) and Recon Technology (RCON up 22.75% at $4.10) drew momentum traders, whereas uCloudlink (UCL down 20.92% at $0.39) slid sharply.
Market context indicates a bifurcated landscape: explosive gains in select health-care and consumer-tech names contrast with profit-taking across parts of the semiconductor complex and pockets of retail, as traders monitor upcoming earnings, Fed minutes and a sizeable Treasury auction that could sway rate expectations.
Other Markets
• 10-year U.S. Treasury yield fell 0.38%, to 4.69%.
• U.S. Dollar Index fell 0.22% to 99.43.
• WTI crude oil futures rose 0.71% to 84.66 USD/barrel; COMEX gold futures fell 0.03% to 4419.20 USD/ounce.
Key News
1. Nebius launched a USD 4.5 billion convertible-notes sale to finance AI cloud expansion. The offering spans 2030 and 2034 tranches, with an added option for underwriters to purchase up to USD 675 million more. Proceeds target new data centers, GPU procurement and debt exchanges, and the stock retreated sharply in pre-market dealings.
2. Moderna and Merck unveiled Phase 3 results showing their personalized melanoma vaccine met its main goal, propelling Moderna shares higher. The Intismeran-Keytruda combination cut recurrence risk versus standard therapy while maintaining a tolerable safety profile. The partners said they will engage regulators to expedite filings.
3. Target raised its full-year sales outlook after a third consecutive quarter of comparable-sales growth. Price cuts on more than 10,000 items and strong digital traffic lifted comps 3.8%, yet tariff-refund gains and cautious forward commentary prompted a pre-open share pullback.
4. Lowe’s trimmed its annual comparable-sales view to flat as homeowners defer big renovation projects. Management cited elevated mortgage rates and softer housing turnover for reduced demand on kitchens, bathrooms and flooring, sending shares lower ahead of the bell.
5. Estee Lauder projected fiscal-year earnings above consensus, supported by resilient demand for premium fragrances and skincare. The “Beauty Reimagined” strategy—centered on innovation and supply-chain efficiencies—has preserved margins; shares gained in early trading.
6. SK Hynix approved a USD 28 billion share-repurchase and cancellation program to boost shareholder returns. The chipmaker also pledged to return at least half of free cash flow from 2025-2027 through buybacks and dividends, lifting its U.S. listing in pre-market action.
7. Samsung Electronics lifted foundry wafer prices by up to 15% amid tight AI-chip capacity. Sources said higher quotes affect 4 nm to 8 nm nodes and mark a turnaround for the loss-making foundry unit, underscoring industry-wide supply constraints.
8. Weibo reported second-quarter revenue growth but a sharp fall in net income as advertising remained sluggish. Value-added services climbed 19%, yet operating margin slipped to 26%, prompting management to highlight ongoing AI-driven product upgrades to revive monetization.
9. Nasdaq set Dec. 6 for the launch of an overnight session, moving toward 23-hour trading five days a week. The exchange said the new 9 p.m.–4 a.m. ET window aims to accommodate global demand and awaits final regulatory clearances.
10. The U.S. Treasury will tap markets for USD 16 billion in 20-year bonds, testing appetite amid multidecade-high yields. Traders expect pricing near 5.28%, reflecting concerns over sustained deficits and tighter Federal Reserve policy, with potential ripple effects on long-term borrowing costs.
Sources: Reuters, Dow Jones, Tiger Newspress, public market data
Disclaimer: For informational purposes only; not investment advice.
